SKY-0515

Name: SKY-0515 in Huntington's disease: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-16T18:00:43-04:00

Huntington's disease

Manufacturer: Skyhawk Therapeutics
Regulatory submission: TGA provisional approval application submitted March 2026
Launch: Anticipated as early as 2027, market not specified
Last updated: October 1, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

Mechanistic classification

“SKY-0515 is an investigational, orally available, brain-penetrant small molecule RNA splicing modulator developed using Skyhawk’s novel RNA-splicing platform.” (opens the source at this quote in a new tab)

AHFS classification

No evidence found.